ArticleBMC neurology2025
Global burden trends of idiopathic epilepsy in young adults from 1990 to 2035: based on the global burden of disease study 2021.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEpilepsy is a prevalent neurological condition that greatly affects the quality of life of those affected, with increasing rates of incidence and prevalence. This study aims to evaluate the global, regional, and national burdens of idiopathic epilepsy (IE) in individuals aged 15 to 49 from 1990 to 2021 via data from the Global Burden of Disease (GBD) Study and to project trends through 2035.
methodsUsing the GBD database 2021, we assessed the burden of IE through metrics involving incidence, prevalence, mortality, and disability-adjusted life years (DALYs). Statistical methods included joinpoint regression for annual percent change (APC), estimated annual percentage change (EAPC), and Bayesian age-period-cohort (BAPC) modeling for projections.
resultsIn 2021, there were 11.48 million (95% UI, 8.35-14.75) young adults with IE, with global incidence, prevalence, mortality and DALY rates of 37.57 (95% UI, 26.28-50.70), 290.83 (211.42-373.58), 1.64 (1.38-1.83) and 185.09 (144.06-230.00) per 100,000 people, respectively. From 1990 to 2021, incidence and prevalence rates increased by 8.51% and 5.7%, respectively, but these increases were not statistically significant. In contrast, mortality and DALY rates significantly decreased by 15.42% and 12.67%, respectively. The 15-19 age group consistently had the highest incidence and prevalence rates, which declined with age. Regionally, high sociodemographic index (SDI) areas consistently presented the highest incidence and prevalence rates, whereas low-SDI regions always exhibited the highest mortality and DALY rates. Besides, males presented higher mortality rates than females. Forecasts for 2035 suggested that the global incidence and prevalence rates of IE would keep rising, whereas mortality and DALY rates were projected to decline.
conclusionThe global burden of IE among young adults remains substantial. To effectively address the evolving global impact of this neurological disorder, it is crucial to prioritize policies and allocate resources accordingly. This will enable the implementation of targeted interventions aimed at improving healthcare access, promoting early diagnosis, and providing treatment in low-resource areas, ultimately reducing future burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.